Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors
Condition(s):Malignant Rhabdoid Tumor; Atypical Teratoid Rhabdoid TumorLast Updated:August 3, 2022Recruiting
Hide Studies Not Open or Pending
Condition(s):Malignant Rhabdoid Tumor; Atypical Teratoid Rhabdoid TumorLast Updated:August 3, 2022Recruiting
Condition(s):Malignant Rhabdoid Tumors (MRT); NeuroblastomaLast Updated:November 22, 2019Terminated
Condition(s):Childhood Atypical Teratoid/Rhabdoid Tumor; Rhabdoid Tumor of the KidneyLast Updated:August 7, 2018Withdrawn
Condition(s):Rhabdoid Tumor; Atypical Teratoid/Rhabdoid Tumor; Malignant Rhabdoid Tumor; Recurrent Brain Tumor, ChildhoodLast Updated:June 8, 2022Terminated
Condition(s):Kidney CancerLast Updated:May 18, 2016Completed
Condition(s):Rhabdoid Neoplasm of CNSLast Updated:August 24, 2017Terminated
Condition(s):Brain and Central Nervous System Tumors; Kidney CancerLast Updated:July 14, 2016Completed
Condition(s):Childhood Atypical Teratoid/Rhabdoid TumorLast Updated:March 2, 2022Active, not recruiting
Condition(s):Brain and Central Nervous System TumorsLast Updated:October 15, 2009Completed
Condition(s):Brain and Central Nervous System TumorsLast Updated:January 6, 2022Active, not recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.